Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

Journal of Clinical Lipidology

Volumn 9, Issue 2, 2015, Pages 201-209

  Santos, Raul D ^a   Raal, Frederick J ^b   Donovan, Joanne M ^c   Cromwell, William C ^d,e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c GENZYME CORPORATION   (United States)

^d Lipoprotein and Metabolic Disorders Institute   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense RNA; Apolipoprotein B; Apolipoprotein C III; Intermediate density lipoprotein; Lipoprotein particles

Indexed keywords

APOLIPOPROTEIN B; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PLACEBO; TRIACYLGLYCEROL; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLIGONUCLEOTIDE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TERTIARY CARE CENTER; TRIACYLGLYCEROL BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; GENETICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE; PATHOLOGY;

ADULT; APOLIPOPROTEIN B-100; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OLIGONUCLEOTIDES;

EID: 84928823457     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.12.008     Document Type: Article

References (46)

1. F.J. Raal, G.J. Pilcher, and V.R. Panz Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy Circulation 124 2011 2202 2207
2. A.C. Goldberg, P.N. Hopkins, and P.P. Toth Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 2011 133 140
3. D.J. Rader, J. Cohen, and H.H. Hobbs Monogenic hypercholesterolemia: new insights in pathogenesis and treatment J Clin Invest 111 2003 1795 1803
4. A. Endo, Y. Tsujita, M. Kuroda, and K. Tanzawa Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase Eur J Biochem 77 1977 31 36
5. M.S. Brown, and J.L. Goldstein A receptor-mediated pathway for cholesterol homeostasis Science 232 1986 34 47
6. J.S. Millar, C. Maugeais, and K. Ikewaki Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production Arterioscler Thromb Vasc Biol 25 2005 560 565
7. A.D. Sniderman, J. De Graaf, and P. Couture Regulation of plasma LDL: the apoB paradigm Clin Sci (Lond) 118 2010 333 339
8. C. Gagne, D. Gaudet, E. Bruckert for the Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia Circulation 105 2002 2469 2475
9. KYNAMRO (Mipomersen Sodium) 2013 Genzyme Corporation Cambridge, MA [package insert]
10. M.K. Ito ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense? Ann Pharmacother 41 2007 1669 1678
11. F.J. Raal, R.D. Santos, and D.J. Blom Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
12. E.A. Stein, R. Dufour, and C. Gagne Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
13. M.P. McGowan, J.C. Tardif, and R. Ceska Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 7 2012 e49006 10.1371/journal.pone.0049006
14. G.S. Thomas, W.C. Cromwell, S. Ali, W. Chin, J.D. Flaim, and M. Davidson Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 62 2013 2178 2184
15. J.D. Otvos, E.J. Jeyarajah, and W.C. Cromwell Measurement issues related to lipoprotein heterogeneity Am J Cardiol 90 2002 22i 29i
16. W.C. Cromwell, and J.D. Otvos Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl Am J Cardiol 98 2006 1599 1602
17. S. Kathiresan, J.D. Otvos, and L.M. Sullivan Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 2006 20 29
18. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42
19. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
20. A.D. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.P. Despres, and B. Lamarche Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177
21. E.A. Stein, A. Sniderman, and P. Laskarzewski Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 96 2005 36K 43K discussion 34K-35K
22. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk of future cardiovascular disease in the Framingham offspring study: implications for LDL management J Clin Lipidol 1 2007 583 592
23. J.H. Contois, J.P. McConnell, and A.A. Sethi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
24. A.D. Sniderman, K. Williams, and J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
25. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
26. P.S. Jellinger, D.A. Smith, A.E. Mehta AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis Endocr Pract 18 suppl 1 2012 1 78
27. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
28. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations Can J Cardiol 25 2009 567 579
29. Z. Reiner, A.L. Catapano, G. De Backer for the ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
30. T.G. Cole, J.H. Contois, and G. Csako Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices Clin Chem 59 2013 752 770
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report 2002 National Institutes of Health. National Heart, Lung, and Blood Institute Bethesda, MD NIH Publication No. 02-5215
32. E.J. Jeyarajah, W.C. Cromwell, and J.D. Otvos Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 2006 847 870
33. V. Panz, A. Immelman, J. Paiker, G. Pilcher, and F. Raal High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia Metab Syndr Relat Disord 10 2012 351 357
34. A. Festa, R. D'Agostino Jr., and L. Mykkanen LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study Diabetes Care 22 1999 1688 1693
35. A. Ambrosch, I. Muhlen, and D. Kopf LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects Diabetes Care 21 1998 2077 2084
36. R.C. Ho, K. Davy, B. Davy, and C.L. Melby Whole-body insulin sensitivity, low-density lipoprotein (LDL) particle size, and oxidized LDL in overweight, nondiabetic men Metabolism 51 2002 1478 1483
37. M.W. Stewart, M.F. Laker, and R.G. Dyer Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia Arterioscler Thromb 13 1993 1046 1052
38. L. Mykkanen, S.M. Haffner, D.L. Rainwater, P. Karhapaa, H. Miettinen, and M. Laakso Relationship of LDL size to insulin sensitivity in normoglycemic men Arterioscler Thromb Vasc Biol 17 1997 1447 1453
39. J.E. Paiker, F.J. Raal, R. Waisberg, and E.P. Buthelezi Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemia: which is more important? Clin Chim Acta 314 2001 167 173
40. W. Patsch, R. Ostlund, I. Kuisk, R. Levy, and G. Schonfeld Characterization of lipoprotein in a kindred with familial hypercholesterolemia J Lipid Res 23 1982 1196 1205
41. M.K. Tilly-Kiesi, and M.J. Tikkanen Differential low density lipoprotein hydrated density distribution in female and male patients with familial hypercholesterolemia Clin Chim Acta 201 1991 65 74
42. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia C.R. Scriver, L.H. Ellenson, N.A. Ellis, J.L. German, A. Kukreja, N.K. Maclaren, The Metabolic and Molecular Bases of Inherited Disease 8th ed 2000 McGraw-Hill, Medical Publishing Division New York 2863 2913
43. C.J. Packard Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein Biochem Soc Trans 31 Pt 5 2003 1066 1069
44. J.D. Furtado, M.K. Wedel, and F.M. Sacks Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins J Lipid Res 53 2012 784 791
45. C. Zheng, C. Khoo, J. Furtado, and F.M. Sacks Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype Circulation 121 2010 1722 1734
46. R.S. Rosenson, and J.A. Underberg Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values Cardiovasc Drugs Ther 27 2013 465 479